LEAP THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
CYPH$2.36-18.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| · | ||
|---|---|---|
| | | Page |
| SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA | 2 | |
| INTRODUCTORY COMMENT | 3 | |
| Part I | | |
| Item 1. | Business | 4 |
| Item 1A. | Risk Factors | 24 |
| Item 1B. | Unresolved Staff Comments | 38 |
| Item 1C. | Cybersecurity | 38 |
| Item 2. | Properties | 39 |
| Item 3. | Legal Proceedings | 39 |
| Item 4. | Mine Safety Disclosures | 39 |
| Part II | | |
| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 40 |
| Item 6. | Reserved | 40 |
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 41 |
| Item 7A. | Quantitative and Qualitative Disclosures About Market Risks | 50 |
| Item 8. | Financial Statements and Supplementary Data | 50 |
| Item 9. | Changes In and Disagreements With Accountants on Accounting and Financial Disclosure | 50 |
| Item 9A. | Controls and Procedures | 50 |
| Item 9B. | Other Information | 51 |
| Item 9C | Disclosures Regarding Foreign Jurisdictions that Prevent Inspections | 51 |
| Part III | | |
| Item 10. | Directors, Executive Officers and Corporate Governance | 51 |
| Item 11. | Executive Compensation | 51 |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 51 |
| Item 13. | Certain Relationships and Related Transactions and Director Independence | 51 |
| Item 14. | Principal Accounting Fees and Services | 51 |
| Part IV | | |
| Item 15. | Exhibits, Financial Statement Schedules | 52 |
| Signatures | | 57 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.